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Detection of PHLPP1a/b in Human and
Mouse Brain by Different Anti-PHLPP1
Antibodies
Travis C. Jackson1, Hülya Bayir1, Milos D. Ikonomovic3, Keri Janesko-Feldman1, Zaichuan Mi2,
Tianyan Gao4, Edwin K. Jackson2 & Patrick M. Kochanek1
1University of Pittsburgh School of Medicine, Department of Critical Care Medicine, Safar Center for Resuscitation Research, 200
Hill Building, 3434 Fifth Avenue, 2University of Pittsburgh School of Medicine, Department of Pharmacology and Chemical Biology,
Bridgeside Point Building 1, 100 Technology Drive, 3University of Pittsburgh School of Medicine, Department of Neurology, 811
Kaufmann Medical Building, 3471 Fifth Avenue, 4University of Kentucky College of Medicine, Department of Molecular & Cellular
Biochemistry, Markey Cancer Center, Lexington, KY 40536, USA.
Pleckstrin homology domain and leucine rich repeat protein phosphatase 1 (PHLPP1) is a member of the
serine/threonine family of phosphatases. It has been studied in organs including brain, heart, pancreas,
adipose, breast, and prostate.HumanPHLPP1 encodes two splice variants - PHLPP1a (,140–150 kDa) and
PHLPP1b (,180–190 kDa). Commercial antibodies are widely used to characterize PHLPP1 proteins in
cells/tissues. Here we validate five different antibodies to detect PHLPP1a/b byWestern blot using PHLPP1
WT/KO mice. All antibodies recognize PHLPP1b in brain. Only a single antibody (Cosmo Bio Co) detects
PHLPP1a (,145–150 kDa). The other four antibodies detect a non-specific signal at ,150 kDa as
evidenced by its abundance in PHLPP1 KO tissues. Results suggest Cosmo antibody is a better reagent to
detect PHLPP1a byWestern blot. In contrast, we found it unsuitable for immunofluorescence applications
in brain.Our findings caution interpretation of the,150 kDa band detected by somePHLPP1 antibodies in
rodent and human tissues. Results also recapitulate the importance of includingmolecular weight standards
in Western blot data to simplify retrospective analysis.
P leckstrin homology domain and leucine rich repeat protein phosphatase 1 (PHLPP1) is a serine/threoninephosphatase with two splice variants. PHLPP1b was first discovered in rat brain1. Neuronal PHLPP1bstrongly inhibits extracellular regulated kinase (ERK) activation2,3, and regulates hippocampal dependent
memory in mice4. PHLPP1a was later cloned from a human cDNA collection5. PHLPP1a overexpression in
cancer cells potently inhibits pro-survival molecule protein kinase B (AKT) and induces cell death5.
Immuno-based techniques such as Western blot are routinely used to study PHLPP1 in cell death and disease.
The first studies characterizing endogenous PHLPP1a by Western blot reported a,140 kDa migrating protein
on SDS-PAGE, using a custommade antibody6. Likewise, we reported a,140 kDa PHLPP1a protein in rat brain
homogenates using a goat polyclonal antibody obtained from Santa Cruz Biotechnology7. Later we reported a
PHLPP1a protein migrating at ,145–150 kDa in rat brain/neuron culture homogenates using a rabbit poly-
clonal antibody purchased from Bethyl laboratories3. The authenticity of endogenous rat ,150 kDa PHLPP1a
was checked by overexpression studies in human embryonic kidney (HEK) cells. We identified a dominant
,150 kDa band only in HEKs overexpressing human PHLPP1a3. Those results led us to speculate that minor
differences observed in PHLPP1a molecular weight (1/2 5 kDa) across studies was likely caused by post-
transcriptional modifications or slight adjustments in experimental factors (e.g. % SDS-PAGE gel used for sample
electrophoresis).
Here we used PHLPP1 gene knockout (KO) mice to unambiguously authenticate target specificity of several
common, as well as seldom used, PHLPP1 antibodies. Gene deletion in KO mice was confirmed by Western
analysis of PHLPP1 in tissue extracts. All antibodies detected the larger ,190 kDa PHLPP1b variant, as con-
firmed by its absence in KOmice. A presumed,150 kDa PHLPP1a signal was detected by four of the antibodies
but equally present in PHLPP1 KO mice – indicating it is likely a non-specific signal. A fifth relatively new
polyclonal commercial antibody uniquely recognized a,145–150 kDa PHLPP1a signal absent in KOmice. Our
findings suggest that antibody selection is a key experimental factor in the study of PHLPP1a (particularly in
brain).
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Results
Brain tissue was harvested from PHLPP1 KO and WT mice. Total
protein extracts were probed with anti-PHLPP1 antibodies (Figure 1).
Antibodies obtained from Bethyl Laboratories (Figure 1A and 1B),
Millipore (Figure 1C), and Cayman Chemical (Figure 1D) all detected
a dominant band in WT mice with apparent molecular mass of
,150 kDa after 15 s film exposure. The,150 kDa band is presumed
to be PHLPP1a. However, contrary to that assumption, we observed
equal levels in KO mouse cortex (Figure 1A–1D-Top Panels).
The PHLPP1b variant was clearly visible after 30 min film expo-
sure using most antibodies (still faint using the Cayman antibody),
and absent in KO extracts (Figure 1A–1D – Lower Panels). A second
dominant ,90 kDa signal was also detected in Bethyl Laboratories
antibody (A300-660A; Figure 1A - asterisk) and Millipore antibody
which has been identified as b-catenin8. b-catenin was not detected
by Bethyl Laboratories antibody (A304-029A; Figure 1B) or Cayman
antibody (Figure 1D). PHLPP1b was readily detected by Cosmo
antibody after 15s film exposure. Cosmo did not detect the
,150 kDa non-specific band (Figure 1E). In addition, it detected a
strong PHLPP1a signal inWT hippocampal extracts as evidenced by
its absence in KOs (Figure 1F). Key experimental factors were con-
trolled for all antibody comparisons (Figure 1G).
We next evaluated the impact of antibody selection by testing if
scientific conclusions change by reagent. Protein expression levels of
PHLPP1a/b in neurons versus astroctyes were investigated. Per-
forming the experiment with Bethyl laboratories antibody (A300-
660A) revealed that ‘‘PHLPP1a’’ (i.e. ,150 kDa band) is highly
expressed in neurons and absent in astrocytes (Figure 2A). Repeat-
ing the experiment with the Cosmo antibody gave different results -
PHLPP1b is the only variant expressed in neurons. PHLPP1a and
PHLPP1b are both expressed in astrocytes (Figure 2B and 2C).
Immunohistochemistry (IHC) is commonly used to define distri-
bution/localization patterns of antigens in cells and tissues. The Cos-
mo antibody appears to be a superior reagent to detect PHLPP1a/b
byWestern analysis. We tested Cosmos’s suitability for IHC applica-
tions in brain. A strong fluorescent signal (RED) was observed in
both cultured primaryWT and KO neurons (Figure 2D). Consistent
with those findings, the Cosmo antibody gave strong fluorescence
(RED) which co-localized with neuronal marker (GREEN) in cor-
tical brain sections (Figure 2E – Lower panel shows YELLOW
overlay). Finally, Cosmo staining (RED) was observed in both
WT/KO mouse brain but failed to co-localize with astrocyte marker
GFAP (Figure 2F).
We next tested PHLPP1 antibodies in human derived cells/tissue.
SHSY5Ys are neuronal-like cells which fully differentiate after 7d
treatment with 10 mM retinoic acid (RA). We compared protein
levels of PHLPP1 variants in undifferentiated (un-Diff) versus 7d
RA differentiated (RA-Diff) neuronal cells. All antibodies detected
,190 kDa PHLPP1b in SHSY5Y homogenates, which appeared un-
affected by differentiation (Figure 3A–4D). In contrast, changes in
presumed PHLPP1a levels (i.e. false PHLPP1a is indicated by a
question mark), are dependent on antibody selection. Bethyl
Laboratories antibody (A300-600A) show that the,150 kDa signal
increased after RA differentiation (Figure 3A). Cayman Chemical
antibody did not recognize a ,150 kDa signal or was below detec-
tion level (Figure 3B). Millipore antibody show that the ,150 kDa
signal decreased after differentiation (Figure 3C). Finally, Cosmo
antibody did not detect a 150 kDa signal (Figure 3D). We also com-
pared PHLPP1 antibodies using human brain homogenates. Bethyl
Laboratories (Figure 3E), Cayman Chemical (Figure 3F), and
Millipore (Figure 3G) detected PHLPP1b and a strong ,150 kDa
signal. Cosmo antibody detected PHLPP1b and a faint ,145–
150 kDa signal (Figure 3G).
Confounding detection of non-specific ,150 kDa signal(s) may
also be problematic in non-CNS tissues. Bethyl Laboratories anti-
body (A300-660A) was first used to screen peripheral organs includ-
ing pancreas, heart, kidney, liver, and lung for the ,150 kDa non-
specific band inWT/KOmice (Figure 4A). Insulin like growth factor
1 receptor (IGF-1R) total, AMP activated protein kinase (AMPK),
and AKT total confirm that protein expression generally varies
across organs (i.e. not unique to PHLPP1). We expanded investiga-
tion of PHLPP1 antibody comparisons in lung, liver, and heart
(organs with high, medium, and low PHLPP1 expression, respect-
ively). Experimental factors were controlled for those experiments
(Figure 4B). Bethyl Laboratories (A300-660A), Bethyl Laboratories
(A304-029A), Millipore, and Cosmo detected PHLPP1b in Lung,
Liver, and Heart (Figure 4C–L and 4N) - except for Millipore/
Heart which was below detection after 20 min exposure (Figure 4M).
Bethyl Laboratories (A300-660A), Bethyl Laboratories (A304-029A),
Millipore detect non-specific,150 kDa protein in lung (Figure 4C–
E). Only Cosmo detects bonafide PHLPP1a in lung and liver
(Figure 4F and 4J, respectively). In our hands, a-Tubulin (i.e. loading
control) was below detection in liver and heart. However, various
non-specific bands detected by different PHLPP1 antibodies clearly
show equal loading across samples.
Discussion
PHLPP1 is abundant in brain1,3. Mounting evidence indicate it is a
key regulator of neuronal survival as well as CNS function.
Hippocampal PHLPP1b overexpression disrupts learning andmem-
ory in mice4. PHLPP1 gene deletion disrupts normal circadian
rhythm in mice9. It also plays a detrimental role in brain injury.
Synaptic PHLPP1 promotes neuronal excitotoxicity after injury10.
It also inhibits protective AKT survival signaling in neurons3.
Consistent with a detrimental role in brain, PHLPP1 KOs are pro-
tected against focal stroke11. Furthermore, hippocampal PHLPP1b
increases after cardiac arrest in rat12. Thus it may alter brain recovery
in different types of cerebral ischemia. Investigators continue to
characterize the spatial, temporal, and relative expression levels of
PHLPP1 in normal and pathological brain as well as other organs.
Immuno-based proteomic techniques are widely utilized for such
studies.
Here we report that PHLPP1 antibodies accurately detect
PHLPP1b (,190 kDa) byWestern analysis. In contrast, many com-
monly used antibodies do not accurately measure PHLPP1a levels
(,145–150 kDa). Non-specific band(s) with similar molecular mass
to PHLPP1a appear to hide the correct signal. A relatively new
commercial PHLPP1 antibody, developed by the Kazusa DNA
Research Institute (sold by Cosmo Bio Co Ltd.), accurately reports
PHLPP1a levels by avoiding detection of overlapping erroneous
,150 kDa non-specific signals. To the best of our knowledge it
has not been used in prior studies.
Recommendations to Standardize PHLPP1 Western Blot Re-
porting. Review of PHLPP1 literature reveal continuing trends to
exclude molecular weight standards in data presentation of Western
blot figures - which may relate to article space/page restrictions. It is
common to find a PHLPP1 figure showing a single cropped band
labeled ‘‘PHLPP1’’ but lacking indication of estimated molecular
mass (e.g.,145 kDa, ,150 kDa, and ,190 kDa) or named vari-
ant (a variant versus b variant). Those parameters should be
acknowledged. Omitting that vital information make it difficult to
retrospectively interpret results in light of our new findings. This is
problematic because 1) PHLPP1a and PHLPP1b variants likely have
different functions and roles in disease pathology, and 2) work here
suggests that a dominant ,150 kDa non-specific signal(s) is
preferentially recognized by many PHLPP1 antibodies – thus
inaccurately describing PHLPP1a signaling changes.
Our results do not contest the validity of past studies using differ-
ent PHLPP1 antibodies (especially if measuring PHLPP1b). Rather,
we simply caution interpretation of the ,150 kDa band. If using
other PHLPP1 antibodies not characterized here, we also recom-
www.nature.com/scientificreports
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Figure 1 | PHLPP1 Antibody Comparison in WT and KO Brain. Cortex and Hippocampus were harvested from PHLPP1 WT/KO mice. 30 mg/well
homogenized brain tissue extract was loaded onto 15 well/4–15% gradient SDS-PAGE gels. PVDF membranes were probed with PHLPP1 antibodies
purchased from (A) Bethyl Laboratories A300-660A, (B) Bethyl Laboratories A304-029A, (C)Millipore, (D)CaymanChemical, and (E and F)Cosmo Bio
Co Ltd. Two film exposure times were collected (TOP images show short film exposure and BOTTOM images show long film exposures of the same blot).
(G) Experimental factors were controlled between antibodies to allow direct comparison of specificity and selectivity. Question mark (?) indicates a
,150 kDa band currently presumed to be PHLPP1a but is abundant in PHLPP1 KO mice. All blots show n52/genotype.
www.nature.com/scientificreports
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Figure 2 | Utility of Cosmo Antibody forWestern and Immunofluorescence Applications.WT/KO culture homogenates were prepared from enriched
primary neurons and astrocytes and loaded onto SDS-PAGE gels (10 mg/well; n53/group). (A) PVDF membranes were probed with Bethyl laboratories
antibody A300-660A (B) PVDF membranes were probed with Cosmo antibody. Protein loading control differences (i.e. a-tubulin) are not caused by
loading control errors. Rather, differences in cell type as verified by total protein stain. (C) Western blot confirming detection of PHLPP1a in KO
astrocyte homogenates probed with the Cosmo antibody (20 mg/well; n56/group). (D) 403 images showing DIV8 cultured WT/KO neurons stained
with neuronal b tubulin III (neuronal marker; GREEN) and Cosmo PHLPP1 antibody (RED). Small boxes in upper right corner show respective
secondary only controls. Little to no staining was observed. (E) 203 images of cortex in PHLPP1 KO stained neuronal b tubulin III (GREEN) and Cosmo
PHLPP1 antibody (RED). Top image shows RED fluorescence only. Bottom image shows RED/GREEN overlay. (F) 203 images of cortex and dentate
gyrus in PHLPP1WT/KOs stained with GFAP (astrocytes; GREEN) and Cosmo PHLPP1 antibody (RED). Overlays show RED fluorescence does not co-
localize with GREEN fluorescence.
www.nature.com/scientificreports
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mend including knockdown control experiments to verify target
specificity. Notably, some organs such as liver and heart do not
appear to express high levels of non-specific ,150 kDa signal(s) –
simplifying data interpretation in those tissues (PHLPP1b appears to
be the primary signal). In contrast, the,150 kDa non-specific signal
is especially problematic in brain.
Antibody Cross-Reactivity: A Challenge to Experimental Repro-
ducibility. Antibody cross-reactivity remains a universal problem
with immunoassays13–16. Antibody selection might strongly impact
data interpretation - relevant to ongoing discussion concerning
methods to enhance scientific reproducibility. We performed
several simple experiments to demonstrate that PHLPP1 antibody
selection can change data interpretation and fundamentally alter
study conclusions. We first attempted to determine which PHLPP1
variant was highest in neurons versus astrocytes. Results using the
Bethyl antibody suggest that PHLPP1a is highly abundant in
neurons and almost absent in astrocytes (Figure 2A). Results using
Figure 3 | Detection of PHLPP1 Variants in Human Neuronal cells and Brain Tissue. Undifferentiated and differentiated SHSY5Y extracts
(20 mg/well; n52) were probed with (A) Bethyl Laboratories A300-660A, (B) Cayman Chemical, (C) Millipore, and (D) Cosmo Bio Co Ltd. Anti-
PHLPP1 antibodies. Human brain tissues from neurologically diseased patients (n56 patients) were probed with (E) Bethyl Laboratories A300-660A,
(F) Cayman Chemical, (G) Millipore, and (H) Cosmo Bio Co Ltd. Anti-PHLPP1.
www.nature.com/scientificreports
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Figure 4 | PHLPP1 Antibody Comparison in Peripheral Organs from WT and KO Mice. (A) Peripheral WT/KO tissues were harvested in order to
screen other organs for potential interfering non-specific ,150 kDa bands. 20 mg/well pancreas, heart, kidney, liver, and lung were loaded onto SDS-
PAGE, transferred to PVDF, and probed with Bethyl Laboratories A300-660A. (B) Lung, liver, and heart were selected for further analysis. Box shows
experimental factors that were controlled to allow direct comparison of antibody specificity and selectivity. Of note, compared to brain, 10 fold higher
antibody concentrations (0.2 mg/mL) were used to detect PHLPP1 proteins in peripheral tissues. (C–F) Lung tissues were probed for PHLPP1 using
Bethyl Laboratories A300-660A, Bethyl Laboratories A304-029A, Millipore, and Cosmo, respectively. (G–J) Liver tissues were probed for PHLPP1 using
Bethyl Laboratories A300-660A, Bethyl Laboratories A304-029A,Millipore, andCosmo, respectively. (K–N)Heart tissues were probed for PHLPP1 using
Bethyl Laboratories A300-660A, Bethyl Laboratories A304-029A, Millipore, and Cosmo, respectively. All blots show n52/genotype.
www.nature.com/scientificreports
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the Cosmo antibody suggest that PHLPP1a is absent in neurons with
low expression in astrocytes (Figure 2B and 2C). Thus experimental
conclusions/interpretations totally reverse depending on which
antibody is used. We have discredited PHLPP1a results obtained
by the Bethyl antibody (Figure 1 and Figure 4). However, it is hard
to estimate the extent to which non-specific signal(s) have
inadvertently been reported as PHLPP1 in past studies.
Tangentially, we do not know why PHLPP1a (as detected by Cos-
mo) has low expression in cortical neurons. Hippocampus appears to
have relatively high levels of PHLPP1a. Future studies need to re-
evaluate PHLPP1a signaling in different neuronal populations and
glia. Levels may vary by cell type and location.
Our second experiment examined the effect of neuronal differ-
entiation on PHLPP1 variants. Results of those studies also show that
antibody selection dramatically changes data interpretation. The
exact same cell homogenate samples were probed with four PHL-
PP1 antibodies. Bethyl Laboratories antibody revealed a ,150 kDa
band increased after neuronal differentiation. Millipore antibody
revealed a,150 kDa band decreased after neuronal differentiation.
Neither the Cosmo or Cayman antibodies detected a ,150 kDa
band in SHSY5Y homogenates. The correct finding is most likely
that PHLPP1a has low expression in SHSY5Y cells and is not altered
by differentiation (i.e. Cosmo results). The,150 kDa signals detected
by Bethyl Laboratories/Millipore antibodies are likely non-specific
proteins.
Non-specific Signal(s). The identity of potential cross-reacting
,150 kDa proteins detected by some PHLPP1 antibodies remain
unclear. It may be a catenin related signal. A recent report
combining immunoprecipitation and mass spectrometry identified
a ,90 kDa b-catenin cross-reacting signal detected by some
PHLPP1 antibodies8. Of note, Bethyl Laboratories responded to
those concerns by discouraging use of product A300-660A for
immunohistochemisy applications. They also generated a new
PHLPP1 antibody with less reported b-catenin cross-reactivity
(A304-029A)17. We verify that the new Bethyl Laboratories
antibody does not detect b-catenin in brain, lung, liver, and heart.
Nevertheless the improved antibody still appears to detect an
erroneous PHLPP1a signal by Western blot analysis in PHLPP1
KO tissues.
Cross reactivity with PHLPP2, the second isoform of PHLPP, may
be another explanation. PHLPP2 migrates at,150 kDa byWestern
analysis6. Using Bethyl Laboratories antibodies we reported that a
,150 kDa PHLPP1a signal robustly increases with advancing devel-
opmental age in rat hippocampus3. In contrast, PHLPP2 antibody
showed the opposite change – with advancing developmental
age, PHLPP2 protein decreased in the same tissue homogenates.
This suggests that ,150 kDa PHLPP1 signal(s), and ,150 kDa
PHLPP2 signal, are distinctly different proteins. In addition, we
found that PHLPP2 knockdown in vitro fails to decrease the
,150 kDa PHLPP1 signal (unpublished observations). Thus while
it is reasonable to assume that the ,150 kDa PHLPP1 signal might
be PHLPP2, we do not think it the explanation.
PHLPP1a lacks the large n-terminal exon 1 found in PHLPP1b
(Ensemble Gene Code; ENSG00000081913). Lack of exon 1 is the
only reported difference between PHLPP1 variants. Exon 4 was cho-
sen for targeted disruption in PHLPP1 gene KO mice9. It is possible
that the ,150 kDa band present in KO mice is a novel PHLPP1
variant which manages to avoid gene deletion. Such phenomenon
has been described for other proteins. For instance, studies show that
targeted disruption of exon 1 in the P2X7 gene fails to inhibit a
functional protein variant in KO mice. This is due to an alternative
start site downstream of the disrupted exon 118. Exon 4 of the
PHLPP1 gene is not predicted to be spliced or have an alternative
downstream start site. Therefore targeted disruption of exon 4
should equally disturb both PHLPP1a and PHLPP1b protein
expression. Consistent with that idea, PHLPP1a and PHLPP1b pro-
tein expression are absent in PHLPP1 KO brain/astrocytes as detect
by Cosmo antibody (Figure 1F and 2C). Nevertheless, though
unlikely, we cannot currently rule out the possibility that the
,150 kDa signal is a novel PHLPP1 variant that endogenously lacks
exon 4 (thus evading deletion in KO mice but still detected by
PHLPP1 antibodies). In summary, here we show that many
PHLPP1 antibodies recognize a ,150 kDa signal in tissues that
may represent a non-specific band unrelated to PHLPP1a.
Methods
Reagents. PHLPP1 Antibodies: Five anti-PHLPP1 antibodies were obtained from
commercial sources. Publicly available manufacture information for each antibody is
as follows: (1) Bethyl Laboratories Antibody (Cat# A300-660A; Lot#A300-600A-1, 9
amino acid (a.a.) antigen corresponding to the c-terminal side of human PHLPP1a/b;
LPDYYDTPL, 1 mismatch to corresponding mouse sequence). (2) Bethyl
Laboratories Antibody (Cat# A304-029A; antigen mapping somewhere between a.a.
residues 1175-1225 of human PHLPP1. (3) Cayman Chemical Antibody
(Cat#10007191; Lot#151571-151572 & Lot#04400591, 14 a.a. antigen corresponding
to the c-terminal side of human PHLPP1a/b; YQLDQLPDYYDTPL, 4mismatches to
corresponding mouse sequence). (4) Millipore (Cat#07-1341; Lot#NG1820229,
corresponding to the c-terminal side of human PHLPP1a/b). Alpha-Tubulin loading
control was purchased from Cell Signaling technology. Goat anti-rabbit – HRP
secondary was purchased from Life Technologies. (5) Cosmo Bio Co Ltd. (Cat#PRX-
MKA0606AF, Lot#MKA0606AF[FAF01103], 118 a.a. sequence corresponding to the
c-terminal side of mouse PHLPP1b: GSRVEVEVDIHCSRAKEKERQQHLLQ-
VPAEASDEGIVISANEDESGLSKKADFSAVGTIGRRRANGSVAPQERSHN-
VIEVAADAPLRKPGGYFAAPAQPDPDDQFIIPPELEEEVKEI; 5 mismatches to
corresponding human sequence.
Animals. Methods were carried out in accordance with approved guidelines. All
experiments were performed in accordance with relevant guidelines and regulations.
All animal work was approved by the IACUC of the University of Pittsburgh.
Euthanasia protocols follow recommendations established by the American Medical
Veterinary Association Guideline for Euthanasia to minimize animal pain and
suffering. Exon targeting gene deletion strategy to generate PHLPP1 KO mice was
described by Masubuchi et al.9. Heterozygous PHLPP1 mice (1/2) on a B6/129
background were submitted to Jackson Laboratories for rederivation on a
B61129SF1/J oocyte donor background. PHLPP11/1 and2/2micewere breed and
genotyped at the Safar Center for Resuscitation Research. 10–15wk old maleWT/KO
mice were used for tissue collection and Western blot analysis. For PHLPP1
immunofluorescence on whole brain slices, a male KO (age 55wk) and female WT
(age 39wk) were used. Female KOs were bred to male KOs to obtain all KO embryos
for primary neuron and astrocyte culture. Female WT were bred to male WT to
obtain WT cells for culture.
Human Brain Tissue. Methods were carried out in accordance with approved
guidelines. Informed consent was secured from all subjects in this study. Using a
protocol approved by the University of Pittsburgh Medical Center IRB, Committee
for Oversight of Research and Clinical Training Involving Decedents, de-identified
human brain cortex samples (,20–40 mg each) were collected from three
Alzheimer’s and three neurologically diseased patients without Alzheimer, who died
and samples subsequently stored at 280uC. Patient groups were comparable by age
and gender. Tissue samples were homogenized according to procedures detailed
below. Brain extracts were stored at 280uC until biochemical analysis.
Ethics statement concerning animal work and collection of human tissues. The
authors confirm that all experiments were performed in accordance with relevant
guidelines and regulations. Animal work methods were carried out in accordance
with procedures that were approved by the IACUC of the University of Pittsburgh.
Methods of collection for human brain tissues were performed in accordance with
procedures that were approved by an Institutional Review Board committee of the
University of Pittsburgh Medical Center.
Cell Culture. Primary Neurons. PHLPP1 WT and KO embryos were collected from
timed pregnant females (E14–E16). Embryonic brains were isolated and meninges
carefully removed under dissecting microscope. Cortical halves were separated and
placed in ice cold hanks balanced salt solution (HBSS). Tissues were minced 1–2 min
with sterile scissors in a 1.5 mL tube containing HBSS. Tissue was trypzinized for
8 min at 37uC, protease activity quenched with Neurobasal/B27 supplement1 10%
fetal bovine serum (FBS), triturated ,10 times through a fire-polished glass Pasteur
pipette, and dissociated cells counted on a hemacytometer. Neurons were seeded onto
poly-D-lysine coated 6-well plates in Neurobasal/B27 culture media, and maintained
by K media exchange every 3 day. ARA-C was added on day in vitro 3 (DIV) to
prevent glia proliferation. Neurons were harvested for biochemistry on DIV6.
Primary Astrocytes. Postnatal day (PND) 1-2 PHLPP1 WT and KO pups were
collected and brains harvested. Meninges were carefully removed under dissecting
microscope. Hemispheres dissociated by 10 min incubation in trypsin solution,
passed through a 10 mL pipette 10-20X, and protease activity quenched in DMEM/
www.nature.com/scientificreports
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F12/10%FBS (i.e. maintenance media). Total brain mix was seeded onto T75 flasks.
Only astrocytes exponentially proliferate over culture days and serial passages. After
2-3 passages on T75 flasks, WT/KO astrocytes were prepared for downstream
experiments and seeded onto 6-well plates. Human neuronal SHSY5Ys. Cells were
purchased fromATCC. Undifferentiated SHSY5Ys were propagated in Optim-MEM
culture media with 10%FBS on T75 culture flasks. Cells were trypsinized and seeded
onto 6 well plates. Undifferentiated cells were collected for biochemistry 3d after
plating. SHSY5Ys were differentiated over 7d by media replacement with Opti-MEM
containing 10 mM RA 1 1%FBS. Differentiated neurons were harvest for
biochemistry on day 7.
Western Blot Analysis. Tissues and cells were homogenized in RIPA buffer
containing protease inhibitors, phosphatase inhibitors and EDTA. Samples were
pulse-sonicated for 20–30s. Protein concentrations were analyzed using the BCA
assay. Samples were prepared in Laemmli loading buffer. Protein samples were loaded
onto gradient TGX precast SDS-PAGE gels (BioRad): 20 mg/well for human brain
tissue, 30 mg/well for mouse WT/KO tissues, 20 mg/well for human neuronal
SHSY5Y electrophoresis experiments, and 10–20 mg/well for primary neuron and
astrocyte studies. In the latter primary neuron versus astrocyte study, total protein
stain was visualized using reversible Swift Membrane Stain (Fisher Scientific).
Proteins were electrophoresed at ,150 V for ,1 h. Proteins were transferred to
PVDFmembranes (100 V/1.15 h/4uC). Blots were blocked 1 h in tris-buffered saline
with tween-20 (TBST)1 7.5%milk. Primary antibodies were prepared in TBST/milk
and incubated overnight on a rocker at 4uC. Blots were washed 3X in TBS, incubated
2 h in secondary antibody (1:15,000), washed 3X in TBS, incubated 2 min with HRP
detection reagent (PIERCE), and films exposed/developed in a dark room.Antibodies
were individually optimized for detection of PHLPP1 except for Figure 1 and Figure 4
– antibody optimization parameters are equivalent in those studies. Films were
captured on a 600–1200 dpi flatbed scanner and images compiled in Photoshop.
Immunofluorescence. In Vitro Neuron Culture: Sterile 8-well chamber glass culture
slides were treated with poly-D-lysine overnight at 37uC. WT and KO neurons were
seeded onto glass slides. DIV8 neurons were washed with PBS, fixed ,25 min with
4% paraformaldehyde, washed with PBS, cell membrane permeabilized with 0.1%
Trition X-100/PBS, washed with PBS, blocked,45 min with 20% goat serum1 1%
BSA in PBS, and incubated overnight at 4uC with primary antibody dissolved in 3%
goat serum/PBS. Neuronal b-tubulin III (neuron marker) was purchased from
abcam. Wells were washed with PBS, incubated with Alexa Fluor Goat-anti Rabbit
594 and Alexa Fluor Goat-anti mouse 488 (Life Technologies) for,1.5 h.Wells were
washed with PBS, plastic chamber removed, and glass slide mounted with ProLong
Gold Antifade with DAPI (Life Technologies). Images were collected (203
magnification) on a fluorescent microscope (Eclipse 50 Nikon, Melville, NY, USA)
and complied in Photoshop. Ex Vivo Brain Sections: WT and KO mice were
anesthetized, transcardially perfused with PBS followed by 10% formalin. Brains were
collected and post-fixed in 10% formalin followed by 30% sucrose solution. Brains
were sectioned, mounted on glass slides, and incubated with primary rabbit anti-
PHLPP1 antibody (Cosmo) as well as eithermouse anti-neuronal tubulin III (Neuron
Marker) or GFAP (astrocyte marker). Sections were washed and incubated with
Alexa Fluor Goat-anti Rabbit 594 (RED) and Alexa Fluor Goat-anti mouse 488
(GREEN). 203 images were collected on a fluorescent microscope.
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